Sarah C. Rutherford

1.1k total citations
52 papers, 414 citations indexed

About

Sarah C. Rutherford is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Sarah C. Rutherford has authored 52 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pathology and Forensic Medicine, 21 papers in Oncology and 12 papers in Genetics. Recurrent topics in Sarah C. Rutherford's work include Lymphoma Diagnosis and Treatment (35 papers), Chronic Lymphocytic Leukemia Research (12 papers) and CAR-T cell therapy research (10 papers). Sarah C. Rutherford is often cited by papers focused on Lymphoma Diagnosis and Treatment (35 papers), Chronic Lymphocytic Leukemia Research (12 papers) and CAR-T cell therapy research (10 papers). Sarah C. Rutherford collaborates with scholars based in United States, Canada and United Kingdom. Sarah C. Rutherford's co-authors include John P. Leonard, Peter Martin, Jia Ruan, Richard R. Furman, Nancy L. Bartlett, Alex F. Herrera, Zhengming Chen, Sonali M. Smith, Jonathan W. Friedberg and Morton Coleman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Sarah C. Rutherford

48 papers receiving 409 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarah C. Rutherford United States 12 260 199 97 82 64 52 414
Wouter J. Plattel Netherlands 12 313 1.2× 223 1.1× 56 0.6× 61 0.7× 103 1.6× 49 418
Eugene Zhu United States 8 155 0.6× 164 0.8× 81 0.8× 123 1.5× 30 0.5× 11 301
Botond Tímár Hungary 11 176 0.7× 114 0.6× 112 1.2× 156 1.9× 77 1.2× 34 355
Sandra P. Susanibar-Adaniya United States 7 137 0.5× 172 0.9× 121 1.2× 57 0.7× 52 0.8× 28 332
Qingyuan Zhang China 10 226 0.9× 245 1.2× 77 0.8× 66 0.8× 87 1.4× 48 460
Florence Broussais‐Guillaumot France 9 228 0.9× 153 0.8× 27 0.3× 95 1.2× 55 0.9× 14 305
M Andreeff United States 8 137 0.5× 135 0.7× 90 0.9× 42 0.5× 99 1.5× 14 373
Hanne Kuitunen Finland 12 270 1.0× 168 0.8× 40 0.4× 157 1.9× 45 0.7× 45 380
Maria Cristina Pirosa Switzerland 10 156 0.6× 119 0.6× 46 0.5× 52 0.6× 46 0.7× 28 305

Countries citing papers authored by Sarah C. Rutherford

Since Specialization
Citations

This map shows the geographic impact of Sarah C. Rutherford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah C. Rutherford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah C. Rutherford more than expected).

Fields of papers citing papers by Sarah C. Rutherford

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah C. Rutherford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah C. Rutherford. The network helps show where Sarah C. Rutherford may publish in the future.

Co-authorship network of co-authors of Sarah C. Rutherford

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah C. Rutherford. A scholar is included among the top collaborators of Sarah C. Rutherford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah C. Rutherford. Sarah C. Rutherford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rutherford, Sarah C., et al.. (2025). The future of follicular lymphoma management: strategies on the horizon. Blood. 146(15). 1792–1801.
2.
Rutherford, Sarah C., Jun Yin, Levi Pederson, et al.. (2024). Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma. Blood Advances. 8(6). 1464–1468. 2 indexed citations
3.
4.
Ruan, Jia, Alison J. Moskowitz, Zhengming Chen, et al.. (2024). Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL). Blood. 144(Supplement 1). 1693–1693. 1 indexed citations
5.
Rutherford, Sarah C., et al.. (2024). The Management of older patients with Hodgkin lymphoma: implications of S1826. Seminars in Hematology. 61(4). 236–244. 2 indexed citations
6.
Qualls, David, Michael J. Buege, Phuong Dao, et al.. (2022). Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study. Blood. 140(Supplement 1). 787–789. 16 indexed citations
7.
Dickinson, Michael, Javier Briones, Alex F. Herrera, et al.. (2021). Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. Blood Advances. 5(22). 4762–4770. 29 indexed citations
8.
George, Login S., et al.. (2021). Unmet mental health needs in patients with advanced B-cell lymphomas. Palliative & Supportive Care. 20(3). 328–333. 5 indexed citations
9.
Marullo, Rossella, María V. Revuelta, Nahuel Zamponi, et al.. (2020). XPO1 Relieves MYC-Induced Replication Stress Limiting the Immunogenicity of DLBCL Cells. Blood. 136(Supplement 1). 18–18. 3 indexed citations
10.
Trevino, Kelly M., et al.. (2019). Illness Understanding and Advance Care Planning in Patients with Advanced Lymphoma. Journal of Palliative Medicine. 23(6). 832–837. 8 indexed citations
11.
Rutherford, Sarah C.. (2019). Surveillance scanning in lymphoma.. PubMed. 17(6). 352–359. 4 indexed citations
12.
Dickinson, Michael, Alex F. Herrera, Eva González‐Barca, et al.. (2019). BET INHIBITOR RG6146, VENETOCLAX, AND RITUXIMAB IS A HIGHLY ACTIVE REGIMEN IN RELAPSED/REFRACTORY (R/R) DLBCL: INITIAL REPORT OF PHASE 1B SAFETY, BIOMARKER, AND RESPONSE DATA. Hematological Oncology. 37(S2). 174–175. 1 indexed citations
13.
14.
Rutherford, Sarah C., Ângela Aguirres Fachel, Sheng Li, et al.. (2017). DLBCL-Derived Exosomes Provide Key Insights into Genomic Landscape in Cell of Origin and May Lead to a Novel Method of Surveillance and Therapeutic Intervention. Blood. 130. 5132–5132. 2 indexed citations
15.
Martin, Peter, Richard R. Furman, Sarah C. Rutherford, et al.. (2015). Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. Leukemia & lymphoma. 56(11). 3065–3070. 21 indexed citations
16.
Rutherford, Sarah C., Ashish Saxena, Jennifer Ishii, et al.. (2014). Characterization of DLBCL-Derived Exosomes and Investigation of Their Biological Properties. Blood. 124(21). 3021–3021. 1 indexed citations
17.
Martin, Peter, Sarah C. Rutherford, & John P. Leonard. (2012). Splenic lymphomas: is there still a role for splenectomy?. PubMed. 26(2). 204, 206–204, 206. 1 indexed citations
18.
Williams, Michael E., Sarah C. Rutherford, Yunjia Tang, & John B. Cousar. (2009). Nuclear Expression of the Sox 11 Transcription Factor in Mantle Cell Lymphoma, and Cytoplasmic Expression in Follicular Lymphoma and Multiple Myeloma: Pathogenetic Implications.. Blood. 114(22). 2925–2925. 1 indexed citations
19.
Rutherford, Sarah C., Biree Andemariam, Rebecca Elstrom, et al.. (2008). FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leukemia & lymphoma. 49(4). 719–726. 11 indexed citations
20.
Taylor, Angela M., Feng Li, Ross G. Gerrity, et al.. (2005). Hyperlipemia and Oxidation of LDL Induce Vascular Smooth Muscle Cell Growth: An Effect Mediated by the HLH Factor Id3. Journal of Vascular Research. 43(2). 123–130. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wouter J. Plattel Breakdown of academic impact, for papers by Eugene Zhu Breakdown of academic impact, for papers by Botond Tímár Breakdown of academic impact, for papers by Sandra P. Susanibar-Adaniya Breakdown of academic impact, for papers by Qingyuan Zhang Breakdown of academic impact, for papers by Florence Broussais‐Guillaumot Breakdown of academic impact, for papers by M Andreeff Breakdown of academic impact, for papers by Hanne Kuitunen Breakdown of academic impact, for papers by Maria Cristina Pirosa
Rankless by CCL
2026